[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid-19-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid-19-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,60,91,124,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100651314","epigenetic-changes-in-long-covid-patients-100651314",false,"NCT07757620","Epigenetic Changes in Long COVID Patients","Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets","ECLIPSE","Inclusion Criteria (Post COVID-19 patients):\n\n* Age ≥ 18 years.\n* Previous SARS-CoV-2 infection documented by molecular or serological testing.\n* Absence of persistent symptoms 2 months after acute infection.\n* Willingness to provide written informed consent.\n\nInclusion Criteria (Long COVID-19 patients):\n\n* Age ≥ 18 years.\n* Previous SARS-CoV-2 infection documented by molecular or serological testing.\n* Persistent symptoms at least 2 months after acute infection, according to the WHO definition of long COVID \\[https:\u002F\u002Fwww.who.int\u002Feurope\u002Fnews-room\u002Ffact-sheets\u002Fitem\u002Fpost-covid-19-condition\\].\n* Willingness to provide written informed consent.\n\nInclusion Criteria (Control Group):\n\n* Age ≥ 18 years.\n* No previous SARS-CoV-2 infection (documented by serology).\n* Blood sample collected according to the COVID-BioVac protocol (NCT05276388) before the first administration of the SARS-CoV-2 vaccine.\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Presence of severe systemic autoimmune diseases or congenital\u002Facquired immunodeficiencies that may confound the interpretation of immunological data.\n* Current systemic immunosuppressive therapy or treatment within the last 6 months prior to enrollment.\n* Active malignancies or those treated within the last 12 months (except basal or squamous cell carcinomas in situ).\n* Pregnancy or breastfeeding at the time of enrollment.\n* Any other clinical condition that, in the investigator's opinion, could compromise the reliability of the data collected.",true,"ALL","18 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the understanding of the biological mechanisms underlying long COVID and to identify molecular biomarkers that may support its diagnosis, prognosis, and future precision medicine approaches in adults with long COVID, adults who have fully recovered from COVID-19, and healthy control participants.\n\nThe main questions it aims to answer are:\n\n* What molecular, immunological, epigenetic, and microbiome profiles distinguish individuals with long COVID from recovered COVID-19 participants and healthy controls?\n* How are viral persistence, immune dysregulation, and alterations in the gut-immune axis associated with the development and clinical manifestations of long COVID?\n* Which molecular biomarkers may improve disease diagnosis, patient stratification, and the identification of potential therapeutic targets?\n\nParticipants will:\n\n* Undergo clinical evaluation and provide information about their medical history and symptoms.\n* Provide biological samples, including blood and, when clinically indicated, intestinal biopsy tissue collected during routine colonoscopy procedures.\n* Undergo comprehensive molecular analyses, including immunological, epigenetic, transcriptomic, proteomic, and microbiome profiling.\n* Have their clinical and molecular data integrated using advanced computational approaches to identify biological signatures associated with long COVID.\n\nThe results of this study may improve the understanding of the biological mechanisms underlying long COVID and support the development of novel biomarkers and future precision medicine approaches for diagnosis, prognosis, patient stratification, and therapeutic target identification.",[26,27],"Long COVID-19 Syndrome","Long COVID Symptoms",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Long COVID-19","COVID-19","gut","Chronic inflammation","epigenetics","methylation","omics","artificial intelligence","ai","machine learning","Multi-omics approaches","biomarker","Immune aging","genomics","transcriptomics","spatial omics","epigenomics","cytokines","NOT_YET_RECRUITING","2026-08-05",{"date":50,"type":51},"2026-08-11","ACTUAL",{"date":53,"type":22},"2026-09",{"date":55,"type":22},"2027-12",{"name":57,"class":58},"Istituti Clinici Scientifici Maugeri SpA","OTHER",3,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377","NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.","80 Years",{"count":70,"type":22},60,"INTERVENTIONAL",[73],"PHASE2","The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[76,77,26,78,79],"Long COVID","Long COVID Syndrome","PASC","PASC Post Acute Sequelae of COVID 19","RECRUITING","2026-07-13",{"date":83,"type":51},"2026-07-15",{"date":85,"type":51},"2025-07-07",{"date":87,"type":22},"2029-06-30",{"name":89,"class":58},"University of New Mexico",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":68,"enrollmentInfo":98,"targetDuration":4,"studyType":71,"phases":100,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":90},"100583051","evaluating-the-impact-of-a-functional-and-cognitive-strategy-in-patients-with-long-covid-19-100583051","NCT06871293","Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19","Impact of Functional and Cognitive Rehabilitation, in Adults With Chronic Noncommunicable Diseases and Long Covid-19 , on Their Functional and Cognitive Capacity, Quality of Life, and the Evolution of Their Baseline Condition, in Bogotá D.C.","Inclusion Criteria:\n\n* Covid-19 confirmed.\n* History of arterial hypertension or diabetes mellitus before entering the institutional registries of the FCI-IC or HOMIL, institutional registries of the FCI-IC or HOMIL or before having the diagnosis of SARSCoV-2 infection.\n* Persistence of two or more concurrent symptoms, related to Covid-19 prologue, for at least 4 weeks (persistent, intermittent, or intermittent).\n* At least one of these symptoms must have an impact on activities of daily living. They can be physical (fatigue, dyspnea, myalgias, arthralgias) or neuropsychiatric (cognitive, sleep and emotional alterations).\n* Symptoms unexplained by underlying disease or other condition concomitant with SARS-CoV-2 infection. SARS-CoV-2 infection (determined by prior medical history review and participant interview).\n\nparticipant interview).\n\n\\- Ability to read and attend functional and cognitive rehabilitation sessions or to receive the with evidence-based informational messages.\n\nExclusion Criteria:\n\n* Age \\>80 years.\n* Severely advanced baseline comorbidities prior to SARS-CoV-2 infection.\n* Presence of chronic respiratory disease (partial or permanent supplemental oxygen use), cardiac failure (LVEF\\\u003C40%) or advanced renal disease (GFR\\\u003C30%).\n\nheart failure (LVEF\\\u003C40%) or advanced renal disease (GFR\\\u003C30).\n\n* Two hospitalizations in the year prior to admission to the institutional registries of the FCI-IC and the HOMIL for the patient's underlying disease.\n* Dependence on a caregiver.\n* Orthopedic or cardiopulmonary problems that contraindicate the performance of aerobic exercise.\n* Neuropsychiatric or cognitive limitations that limit understanding or following commands and performing attention exercises.",{"count":99,"type":22},374,[101],"NA","This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19.\n\nResearchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19.\n\nParticipants will be randomly assigned to one of two groups:\n\n1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, including supervised physical and cognitive exercises.\n2. Informational support: Receiving weekly evidence-based educational messages for 8 weeks.\n\nParticipants will undergo assessments at baseline, post-intervention, and six months later, including a six-minute walk test, handgrip strength measurement, and questionnaires on disability, anxiety, depression, fatigue, dyspnea, cognitive function, and quality of life.",[26,104,105,106,107,76],"COVID 19","Noncommunicable Disease","Hypertension","Diabetes Mellitus",[109,110,111,112,106,107,113,114],"Covid 19","Sars CoV 2","Post-acute Covid-19 syndrome","Long Covid","Noncommunicable disease","Rehabilitation","2026-04-08",{"date":117,"type":51},"2026-04-13",{"date":119,"type":51},"2025-10-30",{"date":121,"type":22},"2027-01-01",{"name":123,"class":58},"Fundación Cardioinfantil Instituto de Cardiología",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":71,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":90},"100617246","phase-2-immunoadsorption-in-autoimmune-long-covid-100617246","NCT07316127","Immunoadsorption in Autoimmune Long COVID","A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID","TURNLongCOVID","Inclusion Criteria:\n\n* Long COVID based on the WHO-criteria\n* PEM according to the DSQ-PEM\n* BELL's functionality score 20-70%\n* Good health prior to the long COVID diagnosis (WHO performance score 0)\n\nExclusion Criteria:\n\n* Medical history of clinically significant respiratory- or cardiovascular disease\n* Prior interventional cardiac procedure within 3 months prior to randomization\n* Active immunosuppresive treatment for systemic autoimmune disorders\n* Diabetes type 1\n* Solid organ malignancy in the last 5 years\n* Active psychiatric disorder currently under treatment by a psychiatrist\n* BMI \\> 35\n* Pre-existing fatigue\n* Poor performance score prior to the long COVID diagnosis (WHO performance \\>0)\n* Pregnancy or breastfeeding","65 Years",{"count":134,"type":22},70,[73],"Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.\n\nThis study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.\n\nThis research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.",[76,77,26,138],"Post COVID Syndrome",[140,141,142,143],"immunoadsorption","long COVID","post COVID","plasmapheresis","2025-12-18",{"date":146,"type":51},"2026-01-05",{"date":148,"type":22},"2026-01-01",{"date":150,"type":22},"2028-03-12",{"name":152,"class":58},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":71,"phases":163,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":185,"locationsCount":90},"100601455","effects-of-kneipp-hydrotherapy-in-post-covid-19-patients-100601455","NCT07110714","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial","HydroCoVitalB","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":162,"type":22},30,[101],"This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.",[166,167,168,169,26],"Post COVID-19 Condition","Post COVID-19 Condition (PCC)","Post COVID-19","Post COVID-19 Syndrome",[171,172,173,174,175,176,177,141,178],"therapy","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","PCC","post COVID-19","2025-12-01",{"date":181,"type":51},"2025-12-02",{"date":179,"type":51},{"date":184,"type":22},"2027-10-31",{"name":186,"class":187},"Eggensberger OHG","INDUSTRY"]